Distribution of low risk DIN/NPN products as samples

Distribution of low risk DIN/NPN products as samples

Published on May 4, 2020

Author: Teri Dickinson, Manager, Regulatory Affairs, Dell Tech Laboratories Ltd.

Beginning July 1, 2020, industry will be able to distribute certain non-prescription drugs and NHPs as samples as a strategy to encourage their use on a trial basis. This may provide benefits to Canadians, practitioners and pharmacists by increasing their knowledge of available health product options to meet their needs.

Amendments to the Food and Drug Regulations following the ratification of the Canada-United States-Mexico Agreement, now permit the distribution of specific low risk non-prescription drugs and natural health products as samples under certain conditions.  Section 14 of the Food and Drugs Act previously prohibited the distribution of drugs as samples other than to physicians, dentists, veterinary surgeons or pharmacists, under prescribed conditions.

To assist stakeholders with interpreting the legislative and regulatory requirements associated with distributing these samples, Health Canada prepared a new guidance document entitled “Distributing samples of prescription drugs, non-prescription drugs and natural health products”.

Some of the low risk DIN and NPN products that can be distributed directly to consumers include:

  • Personal Care Use Antiseptic Cleansers
  • Sunscreens
  • Acne Therapy Products

References:

Regulations Amending the Food and Drug Regulations (Distribution of Drugs as Samples): SOR/2020-74 - http://www.gazette.gc.ca/rp-pr/p2/2020/2020-04-29/html/sor-dors74-eng.html

Guidance Document on the Distribution of Drugs as Samples - Summary - https://www.canada.ca/en/health-canada/services/drugs-health-products/natural-non-prescription/legislation-guidelines/guidance-documents/distribution-drugs-samples-summary.html

Related Articles

Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada

Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada

What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...

Health Canada changes filing requirements for product monographs

Health Canada changes filing requirements for product monographs

Did you know, effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs? This is for only post-life...

Pragmatic Clinical Trials: Testing Treatments in the Real-World

Pragmatic Clinical Trials: Testing Treatments in the Real-World

What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...